Do analysts recommend CAPS or SOS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Capstone Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 SOS 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation & earnings, CAPS or SOS?

Capstone Therapeutics has higher earnings, but lower revenue than SOS. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Capstone Therapeutics $48.11M 0.08 -$21.23M -$3.35 N/A SOS $154.29M 0.08 -$97.32M N/A N/A

Do analysts prefer CAPS or JBDI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Capstone Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 JBDI 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings and valuation, CAPS or JBDI?

JBDI has lower revenue, but higher earnings than Capstone Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Capstone Therapeutics $48.11M 0.08 -$21.23M -$3.35 N/A JBDI $8.52M 1.52 -$2.72M N/A N/A

Do analysts prefer CLWT or CAPS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Euro Tech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Capstone Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings & valuation, CLWT or CAPS?

Euro Tech has higher earnings, but lower revenue than Capstone Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Euro Tech $13.27M 0.91 $160K N/A N/A Capstone Therapeutics $48.11M 0.08 -$21.23M -$3.35 N/A

Do analysts recommend INEO or CAPS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score INNEOVA 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Capstone Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation and earnings, INEO or CAPS?

INNEOVA has higher revenue and earnings than Capstone Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio INNEOVA $58.42M 0.16 -$400K N/A N/A Capstone Therapeutics $48.11M 0.08 -$21.23M -$3.35 N/A

Do analysts prefer CAPS or MWG?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Capstone Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Multi Ways 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger valuation and earnings, CAPS or MWG?

Multi Ways has lower revenue, but higher earnings than Capstone Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Capstone Therapeutics $48.11M 0.08 -$21.23M -$3.35 N/A Multi Ways $44.77M 0.14 $1.79M N/A N/A

Capstone Therapeutics (CAPS) Competitors

$0.19 +0.00 (+0.91%)

As of 09/3/2026 04:00 PM Eastern

Compare

CAPS vs. SOS, JBDI, CLWT, INEO, and MWG

Should you buy Capstone Therapeutics stock or one of its competitors? Capstone Therapeutics's main competitors and comparable companies include SOS (SOS), JBDI (JBDI), Euro Tech (CLWT), INNEOVA (INEO), and Multi Ways (MWG). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "trading companies & distributors" industry.

How does Capstone Therapeutics compare to SOS?

Capstone Therapeutics (NASDAQ:CAPS) and SOS (NYSE:SOS) are both small-cap industrials companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, dividends, valuation, media sentiment, analyst recommendations, earnings and institutional ownership.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Capstone Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
SOS	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Capstone Therapeutics has a beta of -1.5, indicating that its share price is 250% less volatile than the broader market. Comparatively, SOS has a beta of 2.6, indicating that its share price is 160% more volatile than the broader market.

In the previous week, Capstone Therapeutics' average media sentiment score of 0.00 equaled SOS'saverage media sentiment score.

Company	Overall Sentiment
Capstone Therapeutics	Neutral
SOS	Neutral

SOS has a net margin of 0.00% compared to Capstone Therapeutics' net margin of -36.51%. SOS's return on equity of 0.00% beat Capstone Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Capstone Therapeutics	-36.51%	-144.43%	-40.48%
SOS	N/A	N/A	N/A

2.6% of Capstone Therapeutics shares are held by institutional investors. Comparatively, 1.9% of SOS shares are held by institutional investors. 39.3% of Capstone Therapeutics shares are held by insiders. Comparatively, 2.7% of SOS shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Capstone Therapeutics has higher earnings, but lower revenue than SOS.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Capstone Therapeutics	$48.11M	0.08	-$21.23M	-$3.35	N/A
SOS	$154.29M	0.08	-$97.32M	N/A	N/A

Summary

SOS beats Capstone Therapeutics on 6 of the 9 factors compared between the two stocks.

How does Capstone Therapeutics compare to JBDI?

Capstone Therapeutics (NASDAQ:CAPS) and JBDI (NASDAQ:JBDI) are both small-cap industrials companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership.

In the previous week, JBDI had 2 more articles in the media than Capstone Therapeutics. MarketBeat recorded 2 mentions for JBDI and 0 mentions for Capstone Therapeutics. JBDI's average media sentiment score of 0.69 beat Capstone Therapeutics' score of 0.00 indicating that JBDI is being referred to more favorably in the news media.

Company	Overall Sentiment
Capstone Therapeutics	Neutral
JBDI	Positive

2.6% of Capstone Therapeutics shares are held by institutional investors. 39.3% of Capstone Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Capstone Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
JBDI	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

JBDI has lower revenue, but higher earnings than Capstone Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Capstone Therapeutics	$48.11M	0.08	-$21.23M	-$3.35	N/A
JBDI	$8.52M	1.52	-$2.72M	N/A	N/A

JBDI has a net margin of 0.00% compared to Capstone Therapeutics' net margin of -36.51%. JBDI's return on equity of 0.00% beat Capstone Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Capstone Therapeutics	-36.51%	-144.43%	-40.48%
JBDI	N/A	N/A	N/A

Capstone Therapeutics has a beta of -1.5, suggesting that its share price is 250% less volatile than the broader market. Comparatively, JBDI has a beta of -1.11, suggesting that its share price is 211% less volatile than the broader market.

Summary

JBDI beats Capstone Therapeutics on 8 of the 11 factors compared between the two stocks.

How does Capstone Therapeutics compare to Euro Tech?

Euro Tech (NASDAQ:CLWT) and Capstone Therapeutics (NASDAQ:CAPS) are both small-cap industrials companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, media sentiment, risk, profitability, valuation and earnings.

2.9% of Euro Tech shares are owned by institutional investors. Comparatively, 2.6% of Capstone Therapeutics shares are owned by institutional investors. 79.0% of Euro Tech shares are owned by company insiders. Comparatively, 39.3% of Capstone Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Euro Tech has higher earnings, but lower revenue than Capstone Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Euro Tech	$13.27M	0.91	$160K	N/A	N/A
Capstone Therapeutics	$48.11M	0.08	-$21.23M	-$3.35	N/A

In the previous week, Euro Tech had 2 more articles in the media than Capstone Therapeutics. MarketBeat recorded 2 mentions for Euro Tech and 0 mentions for Capstone Therapeutics. Euro Tech's average media sentiment score of 0.00 equaled Capstone Therapeutics'average media sentiment score.

Company	Overall Sentiment
Euro Tech	Neutral
Capstone Therapeutics	Neutral

Euro Tech has a beta of 0.87, meaning that its stock price is 13% less volatile than the broader market. Comparatively, Capstone Therapeutics has a beta of -1.5, meaning that its stock price is 250% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Euro Tech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Capstone Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Euro Tech has a net margin of 0.00% compared to Capstone Therapeutics' net margin of -36.51%. Euro Tech's return on equity of 0.00% beat Capstone Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Euro Tech	N/A	N/A	N/A
Capstone Therapeutics	-36.51%	-144.43%	-40.48%

Summary

Euro Tech beats Capstone Therapeutics on 9 of the 10 factors compared between the two stocks.

How does Capstone Therapeutics compare to INNEOVA?

INNEOVA (NASDAQ:INEO) and Capstone Therapeutics (NASDAQ:CAPS) are both small-cap industrials companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk.

In the previous week, INNEOVA's average media sentiment score of 0.00 equaled Capstone Therapeutics'average media sentiment score.

Company	Overall Sentiment
INNEOVA	Neutral
Capstone Therapeutics	Neutral

INNEOVA has a beta of 1.17, suggesting that its stock price is 17% more volatile than the broader market. Comparatively, Capstone Therapeutics has a beta of -1.5, suggesting that its stock price is 250% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
INNEOVA	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Capstone Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

INNEOVA has a net margin of 0.00% compared to Capstone Therapeutics' net margin of -36.51%. INNEOVA's return on equity of 0.00% beat Capstone Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
INNEOVA	N/A	N/A	N/A
Capstone Therapeutics	-36.51%	-144.43%	-40.48%

INNEOVA has higher revenue and earnings than Capstone Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
INNEOVA	$58.42M	0.16	-$400K	N/A	N/A
Capstone Therapeutics	$48.11M	0.08	-$21.23M	-$3.35	N/A

2.6% of Capstone Therapeutics shares are owned by institutional investors. 39.3% of Capstone Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

INNEOVA beats Capstone Therapeutics on 7 of the 9 factors compared between the two stocks.

How does Capstone Therapeutics compare to Multi Ways?

Capstone Therapeutics (NASDAQ:CAPS) and Multi Ways (NYSE:MWG) are both small-cap industrials companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, earnings, risk, analyst recommendations, institutional ownership, media sentiment and dividends.

Capstone Therapeutics has a beta of -1.5, suggesting that its stock price is 250% less volatile than the broader market. Comparatively, Multi Ways has a beta of 1.22, suggesting that its stock price is 22% more volatile than the broader market.

Multi Ways has a net margin of 0.00% compared to Capstone Therapeutics' net margin of -36.51%. Multi Ways' return on equity of 0.00% beat Capstone Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Capstone Therapeutics	-36.51%	-144.43%	-40.48%
Multi Ways	N/A	N/A	N/A

Multi Ways has lower revenue, but higher earnings than Capstone Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Capstone Therapeutics	$48.11M	0.08	-$21.23M	-$3.35	N/A
Multi Ways	$44.77M	0.14	$1.79M	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Capstone Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Multi Ways	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

2.6% of Capstone Therapeutics shares are held by institutional investors. Comparatively, 0.8% of Multi Ways shares are held by institutional investors. 39.3% of Capstone Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Multi Ways had 1 more articles in the media than Capstone Therapeutics. MarketBeat recorded 1 mentions for Multi Ways and 0 mentions for Capstone Therapeutics. Capstone Therapeutics' average media sentiment score of 0.00 equaled Multi Ways'average media sentiment score.

Company	Overall Sentiment
Capstone Therapeutics	Neutral
Multi Ways	Neutral

Summary

Multi Ways beats Capstone Therapeutics on 7 of the 11 factors compared between the two stocks.

Get Capstone Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CAPS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CAPS vs. The Competition

Export

Metric	Capstone Therapeutics	Trading Companies & Distributors Industry	Industrials Sector	NASDAQ Exchange
Market Cap	$3.84M	$9.08B	$10.32B	$12.73B
Dividend Yield	N/A	3.43%	97.27%	8.86%
P/E Ratio	-0.06	27.00	26.28	25.38
Price / Sales	0.08	22.85	411.30	97.56
Price / Cash	N/A	48.50	23.94	52.26
Price / Book	0.31	3.17	4.60	6.14
Net Income	-$21.23M	$371.61M	$610.41M	$349.01M
7 Day Performance	2.95%	-1.30%	-1.11%	-0.27%
1 Month Performance	-27.22%	-2.49%	-1.77%	0.68%
1 Year Performance	-83.46%	4.81%	9.74%	14.84%

Capstone Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CAPS Capstone Therapeutics	0.8336 of 5 stars	$0.19 +0.9%	N/A	-83.9%	$3.84M	$48.11M	N/A	38
SOS SOS	0.3869 of 5 stars	$0.85 -6.5%	N/A	-38.4%	$14.72M	$154.29M	N/A	170
JBDI JBDI	0.4749 of 5 stars	$1.26 -5.9%	N/A	-32.7%	$12.73M	$8.44M	N/A	121	News Coverage Earnings Report Analyst Upgrade Gap Down
CLWT Euro Tech	0.6566 of 5 stars	$1.66 +3.4%	N/A	+16.5%	$11.95M	$13.27M	N/A	40
INEO INNEOVA	N/A	$0.59 +7.0%	N/A	-39.0%	$9.12M	$58.42M	N/A	N/A	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CAPS) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Capstone Therapeutics (CAPS) Competitors

CAPS vs. SOS, JBDI, CLWT, INEO, and MWG

How does Capstone Therapeutics compare to SOS?

Summary

How does Capstone Therapeutics compare to JBDI?

Summary

How does Capstone Therapeutics compare to Euro Tech?

Summary

How does Capstone Therapeutics compare to INNEOVA?

Summary

How does Capstone Therapeutics compare to Multi Ways?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CAPS vs. The Competition

Capstone Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Capstone Therapeutics (CAPS) Competitors

CAPS vs. SOS, JBDI, CLWT, INEO, and MWG

How does Capstone Therapeutics compare to SOS?

Do analysts recommend CAPS or SOS?

Which has more risk and volatility, CAPS or SOS?

Does the media favor CAPS or SOS?

Is CAPS or SOS more profitable?

Do insiders and institutionals hold more shares of CAPS or SOS?

Which has stronger valuation & earnings, CAPS or SOS?

Summary

How does Capstone Therapeutics compare to JBDI?

Does the media favor CAPS or JBDI?

Do insiders & institutionals hold more shares of CAPS or JBDI?

Do analysts prefer CAPS or JBDI?

Which has better earnings and valuation, CAPS or JBDI?

Is CAPS or JBDI more profitable?

Which has more volatility and risk, CAPS or JBDI?

Summary

How does Capstone Therapeutics compare to Euro Tech?

Do institutionals & insiders have more ownership in CLWT or CAPS?

Which has higher earnings & valuation, CLWT or CAPS?

Does the media prefer CLWT or CAPS?

Which has more risk and volatility, CLWT or CAPS?

Do analysts prefer CLWT or CAPS?

Is CLWT or CAPS more profitable?

Summary

How does Capstone Therapeutics compare to INNEOVA?

Does the media prefer INEO or CAPS?

Which has more volatility & risk, INEO or CAPS?

Do analysts recommend INEO or CAPS?

Is INEO or CAPS more profitable?

Which has better valuation and earnings, INEO or CAPS?

Do institutionals and insiders believe in INEO or CAPS?

Summary

How does Capstone Therapeutics compare to Multi Ways?

Which has more volatility & risk, CAPS or MWG?

Is CAPS or MWG more profitable?

Which has stronger valuation and earnings, CAPS or MWG?

Do analysts prefer CAPS or MWG?

Do insiders and institutionals believe in CAPS or MWG?

Does the media favor CAPS or MWG?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CAPS vs. The Competition

Capstone Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools